Evaluating Patient-Defined Priorities for Female Patients with Bladder Cancer
- PMID: 38993211
- PMCID: PMC11181836
- DOI: 10.3233/BLC-200397
Evaluating Patient-Defined Priorities for Female Patients with Bladder Cancer
Abstract
Background: Although bladder cancer is much more common in men than in women, female patients with bladder cancer present with more locally advanced tumors and have worse disease-specific outcomes than male patients, even after controlling for biological differences. There is a paucity of research regarding the optimal approach to caring for female patients with bladder cancer in ways that maximize patient satisfaction, preferences, and values.
Objective: We sought to explore patient-defined priorities and areas in need of improvement for female patients with bladder cancer from the patient perspective.
Methods: We conducted focus group sessions and semi-structured interviews of women treated for bladder cancer to identify patient priorities and concerns until reaching topic saturation. Transcripts were analyzed thematically.
Results: Eight patients with muscle-invasive bladder cancer and six patients with non-muscle-invasive bladder cancer participated in two focus groups and seven interviews total. Three themes emerged as significantly affecting the care experience: physical impacts, mental health and emotional wellbeing, and the patient-provider interaction. Each theme included patient-defined specific recommendations on approaches to optimizing the care experience for women with bladder cancer.
Conclusions: Although most participants were satisfied with the quality of care they received, they identified several opportunities for improvement. These concerns centered around enhancing support for patients' physical and mental needs and strengthening the patient-provider interaction. Efforts to address these needs and reduce gender disparate outcomes via quality improvement initiatives are ongoing.
Keywords: Urinary bladder neoplasms; patient advocacy; qualitative research; quality improvement.
© 2021 – The authors. Published by IOS Press.
Conflict of interest statement
Amanda Vo, Mary Kate Keeter, and Emily Tuchman do not have conflicts of interest related to this work to declare. Alicia Morgans has the following honoraria for advisory board activities to report: Janssen, Sanofi, Astellas, AstraZeneca, Bayer, Dendreon, Myovant, Advanced Accelerator Applications, and Clovis. In addition, Alicia Morgans has the following research collaborations to report: Bayer, Seattle Genetics, Astellas, Sanofi, Dendreon. Joshua Meeks does consulting work for Merck, AstraZeneca, Ferring, Cold Genesys, Janssen, Nucleix, and Foundation Medicine. He is funded for research by Abbvie, Tesaro, Epizyme, Prostate Cancer Foundation, Hope Foundation, VHA, NIH, and DoD. He has received education funding for lectures from AUA, OncLive, University North Carolina, and ASCO. Lastly, Dr. Meeks has clinical trials with SWOG, Genentech, Merck, and AstraZeneca.
Similar articles
-
Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer.Bladder Cancer. 2018 Jan 20;4(1):121-128. doi: 10.3233/BLC-170138. Bladder Cancer. 2018. PMID: 29430512 Free PMC article.
-
Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol.JBI Database System Rev Implement Rep. 2015 Jan;13(1):99-111. doi: 10.11124/jbisrir-2015-1809. JBI Database System Rev Implement Rep. 2015. PMID: 26447011
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
Operationalizing patient-centered cancer care: A systematic review and synthesis of the qualitative literature on cancer patients' needs, values, and preferences.Psychooncology. 2020 Nov;29(11):1723-1733. doi: 10.1002/pon.5500. Epub 2020 Aug 23. Psychooncology. 2020. PMID: 32715542 Free PMC article.
-
Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.Health Technol Assess. 2020 Sep;24(46):1-490. doi: 10.3310/hta24460. Health Technol Assess. 2020. PMID: 32975190 Free PMC article.
References
-
- American Cancer Society. Cancer Facts & Figures 2019. Atlanta, GA: American Cancer Society, 2019.
-
- Dobruch J, Daneshmand S, Fisch M, et al. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. European Urology. 2016;69:300–10. - PubMed
-
- Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009;115:68. - PubMed
-
- Pozzar RA, Berry DL. Gender Differences in Bladder Cancer Treatment Decision Making. Oncology Nursing Forum. 2017;44:204. - PubMed
LinkOut - more resources
Full Text Sources